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Abstract. The notion that gliomas could originate from
mutated glial precursor cells highlights the possibility of
modulating the proliferative and migratory behaviour of glioma
cells by acting on the molecular mechanisms operative during
the development of the Central Nervous System (CNS), but
absent in the normal adult brain. We show that the GL15
glioblastoma derived human cell line displays a high
expression of nestin which, combined with the previously
demonstrated high expression of vimentin, constitutes a
characteristic of astrocyte restricted precursors. We also
show that, in analogy with some leukaemia cells, GL15 cells
display the constitutively phosphorylated form of Janus
kinase 2 (JAK2), a tyrosine kinase expressed during CNS
development but undetectable in the normal adult brain. The
constitutive activation of JAK2 does not result from chromo-
somal aberrations involving the JAK2 gene, but most probably
from abnormally activated transduction systems operative in
glioblastoma cells. We then investigated the effects of
tyrphostin AG490, an inhibitor of JAK2 autophosphorylation,
on GL15 cell growth. In the absence of exogenous growth
factors and cytokines, 10 μM tyrphostin AG490 induces an S
phase arrest, combined with a partial impairment of the G2
phase of the cell cycle. The abnormally activated JAK2 could
then potentially represent a target for a selective pharmaco-
logical approach in glioblastoma cells in which a combination
of glial precursor characteristics and genetic alterations
occurs.
Introduction
The idea that brain tumors could originate from embryonic or
adult precursor cells is the object of intensive investigation
(1,2). The concept that gliomas could originate from mutated
glial precursor cells highlights the possibility of modulating
the proliferative and migratory behaviour of glioma cells by
acting on the molecular mechanisms operative during Central
Nervous System (CNS) development but absent in the normal
adult brain. Some of these mechanisms have been identified
in human gliomas. Therefore the use of specific inhibitors of
the key factors controlling these mechanisms could constitute
a possible experimental approach in the study of gliomas. A
possible candidate is the Janus Kinase 2 (JAK2) protein
tyrosine kinase involved in the downstream effects of some
growth factor and cytokine receptor activation (3). In fact the
expression of JAK2 is evident during CNS development (4,5)
but is undetectable in the normal adult brain (6). The activity
of JAK2 in the normal adult brain seems to be related to
pathological states in which inflammatory cytokines are
involved (7-10).
In our study we investigate the presence of the active
form of JAK2 and the genetic abnormalities involving the
JAK2 gene. Moreover we evaluate the effects of tyrphostin
AG490, the inhibitor of JAK2 activity (11), on the GL15
(12-15) glioblastoma derived human cell line. The analysis
of this glioblastoma derived cell line behaviour, after treat-
ment with AG490, could be considered a specific response of
immature glial populations. In fact GL15 cells constitutively
express vimentin (12), and in this report we show the consti-
tutive expression of nestin. The expression of both vimentin
and nestin, embryonic intermediate filament proteins, has
been considered a characteristic of astrocytic precursors (16).
Tyrphostin AG490 has been successfully used in a mouse
model to selectively inhibit acute lymphoblastic leukaemia
cell growth in vitro and in vivo and it has been demonstrated
that this effect was due to the inhibition of JAK2 (11).
Further studies have also shown that the inhibitory effects on
cell growth by AG490 were selective for human leukaemia
cells in which chromosomal aberrations lead to the consti-
tutive activation of JAK2 (17,18). In these studies AG490
was shown to be able to potently inhibit the proliferation of
leukaemia cells at a concentration that has few inhibitory
effects on normal hematopoiesis.
Our results show that the specific response of the sub-
populations of glioblastoma cells to AG490 is due to the
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presence of molecular mechanisms, operative during glial
cell development but absent in adult glia, combined with the
altered controls of cell cycle progression typical of glio-
blastoma.
Materials and methods
Cell cultures. Cultures of the GL15 glioblastoma multiforme
cell line were grown in minimum essential medium (MEM)
supplemented with 10% heat-inactivated foetal bovine serum
(FBS), 100 IU/ml penicillin G, 100 μg/ml streptomycin, 2 mM
glutamine and 1 mM sodium pyruvate. The flasks were
incubated at 37˚C in a 5% CO2 humidified atmosphere. The
medium was changed twice weekly and the cells were sub-
cultivated when confluent.
After one day of subculturing the GL15 cells were treated
with 10 μM tyrphostin AG490 (Calbiochem) in serum-free
medium, and analysed 3 days after treatment. In all the
experiments the final concentration of dimethyl sulphoxide
(DMSO) was 0.1%. The controls containing the same amount
of DMSO were included at each experimental time point.
Morphological analysis of the cells was performed with a
contrast phase Nikon microscope. Cell count was performed
after trypsinization using a Burker camera.
Indirect immunofluorescence. The cells were extensively
washed with phosphate-buffered saline (PBS), immersed in
cold methanol, kept at -20˚C for 7 min and dried in air. The
cells were then incubated for 60 min at room temperature
with a rabbit anti-GFAP (Dakopatts, Denmark) polyclonal
antibody (diluted 1:300 in PBS containing 0.3% bovine serum
albumin) and washed in PBS. After treatment with tetramethyl-
rhodamin isothiocyanate (TRITC, Sigma) conjugated goat anti-
rabbit IgG (diluted 1:200 in PBS containing 0.3% albumin)
and washing 3x with PBS containing 0.1% Tween-20 and
twice with PBS, the preparations were incubated with 2 μg/ml
DAPI (4,6-diamidino-2-phenylindole) (Sigma) for 5 min and
dried in air. The same procedure was used with a mouse anti-
ß-tubulin antibody (Sigma), diluted 1:50 in PBS containing
0.3% bovine serum albumin and the anti-mouse IgG (Fab
specific), fluorescein isothiocyanate (FITC, Sigma) conjugated
antibody (diluted 1:100), except for a permeabilization step
performed by treatment with PBS containing 0.1% Triton
X-100 for 5 min. The preparations were observed with a
DMRB Leica microscope.
ELISA detection of cytoplasmic nucleosomes. Determination
of the cytoplasmic histone-associated-DNA-fragments was
performed using the Cell Death Detection ELISA (Plus) kit
(Roche), following the instructions of the manufacturer. The
results are expressed as a percentage of the optical density,
resulting from the activity of the peroxidase-conjugated anti-
DNA-antibody complexed with cytoplasmic nucleosomes of
treated cells, compared to the control.
SDS-polyacrylamide gel electrophoresis and immunoblotting.
GL15 cell cultures were washed with PBS and scraped with
62.5 mM Tris-HCl (pH 6.8), 2 mM EDTA, 0.5% Triton X-100,
protease inhibitor cocktail (Sigma), and 0.1% SDS. The protein
content was determined by the Bio-Rad protein assay kit.
The proteins were separated by SDS-PAGE in acryla-
mide gels using the method described by Laemmli (19), then
transferred to nitrocellulose filters according to Towbin et al
(20). The immunolabeling of nestin, GFAP and vimentin was
performed as described by Tognon et al (21). The primary
antibodies were: A rabbit anti-nestin polyclonal antibody
(Chemicon), a rabbit anti-GFAP policlonal antibody
(Dakopatts) and a mouse anti-vimentin monoclonal antibody
(Roche).
When analysing the phosphorylated form of JAK2 by the
rabbit phospho-JAK2 (Tyr1007/1008) antibody (Cell
Signaling Technologies), the phosphatase inhibitor cocktail II
(Sigma) was added to the extraction buffer. The analysis of
the actin content performed by using the mouse anti-actin
monoclonal antibody (ICN Biomedicals) was used as the
control.
The secondary antibodies were the peroxidase-conjugated
goat anti-rabbit immunoglobulins (Pierce) and the peroxidase-
conjugated goat anti-mouse immunoglobulins (Pierce).
The Enhanced Chemiluminescence detection was
performed by using the instructions of ECL™ Western
blotting (Cell Signaling Technologies).
Measurements of cell cycle by flow cytometry. Following the
different treatments, aliquots of the cell suspension were
transferred into centrifuge tubes and washed once with PBS
(400 x g, 7 min), then successively processed for cell cycle
analysis by propidium iodide (PI) staining and flow
cytometry. Briefly, the cell pellet was resuspended in 0.5 ml
hypotonic fluorochrome solution (50 μg/ml PI in 0.1%
sodium citrate plus 0.1% Triton X-100) in 12x75 mm
polypropylene tubes (Becton-Dickinson, Lincoln Park, NJ,
USA). The tubes were kept at 4˚C for at least 30 min before
flow cytometric analysis. The PI fluorescence of the individual
nuclei was measured using a FACScan flow cytometer
(Becton-Dickinson, Mountain View, CA, USA) at a wave-
length of 488 nm. The percentages of the cells in the G0/G1,
S and G2/M phases were calculated using CellFIT cell-cycle
analysis version 2.0.2. software.
Fluorescence in situ hybridization (FISH). Metaphase FISH
was performed with the DNA clone RP1-134N20 for JAK2/
9p24 as previously described (22). The PAC clone belongs
to the Roswell Park Cancer Institute library RP1, http://
www.chori.org/BACPAC, and was kindly provided by
Professor P. Marynen, University of Leuven, Belgium). Five
cells were analysed with a fluorescence microscope (Provis,
Olympus, Milan, Italy) equipped with a CCD camera (Sensys,
Photometrics) run by SmartCapture software (Vysis, Stuttgart,
Germany).
dHPLC. Genomic DNA from GL15 cell lines, and genomic
DNA from blood of a patient affected by Polycythemia Vera
as a positive control for Val(617)Phe mutation, were
extracted using standard procedures. The PCR fragments of
JAK2 exon 12 were amplified using the following oligo-
nucleotide primers: JAK2-F (5' TTCCTGTACCACTCTT
GCTC 3'), JAK2-R (5' TTTCAGGATCACAGCTAGGT 3').
PCRs were performed in a volume of 25 μl, containing 100 ng
genomic DNA, 6 pmol forward and reverse primers, 200 μM
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dNTP, 0.3 U Expand High Fidelity Plus Taq (Roche
Diagnostics, Monza) and buffer 2 (1.75 mM MgCl2). PCRs
were initiated by a denaturation step at 94˚C for 5 min,
followed by 33 cycles at 94˚C for 45 sec, 58˚C for 30 sec,
and 72˚C for 45 sec; a final extension was performed at 72˚C
for 5 min. The 12th coding exon with flanking intron sequences
of the JAK2 gene was screened for Val(617)Phe mutation by
dHPLC (Wave™ System, MD Transgenomic Inc., Omaha,
Nebraska, USA). The PCR products were denatured at 95˚C
for 5 min and cooled down a temperature ramp of 1˚C/min to
65˚C; the last step consisted of 1 min at 65˚C. The samples
were kept cool until 10 μl were automatically inserted into a
preheated reversed phase column based on non-porous (poly-
styrene-divinylbenzene) particles (DNA-Sep, Transgenomic,
San Jose, USA). DNA was eluted on a linear acetonitrile
gradient consisting of buffer A (0.1 M triethylammonium
acetate; TEAA)/buffer B (0.1 M TEAA, 25% acetonitrile).
Gradient elution and melting temperature conditions were
determined using WaveMaker Navigator™ version 1.5.4
software (Transgenomic). On the basis of the PCR product
(419 bp) the nucleotide sequence analysis programme
calculated the melting temperature of the domains contained
in the sequences of interest at 54.2˚C. The electropherograms
from GL15 were compared with the normal sequenced
controls and with the electropherogram generated from the
Polycythemia Vera affected patient.
Results
It is possible that different glioblastoma cell lines could
retain some biochemical regulatory pathways typical of
different glial precursors. The GL15 glioblastoma derived
human cell line has been shown to be tumorigenic in vivo
with the same proliferative and invasive properties of
glioblastoma (23). In this cell line the high expression of
vimentin, an embryonic intermediate filament protein, was
previously shown (12,13). In order to further characterize
this cell line, we analysed the expression of nestin. Our
results show a high expression of nestin in GL15 cells, both
in the absence and in the presence of serum in the culture
medium (Fig. 1A). The high expression of the embryonic
intermediate filament proteins, vimentin and nestin, is
considered a characteristic of astrocyte restricted precursors
(16).
Due to the fact that the expression of JAK2 is develop-
mentally regulated and that this protein tyrosine kinase is
undetectable in the normal adult brain, we analysed the
presence of the active form of JAK2 in GL15 cells as a
possible target for specific pharmacological approaches.
In analogy with some leukaemia cells, the active form
of JAK2 is present in GL15 cells also in the absence of
exogenous growth factors and cytokines: The phosphorylated
form of JAK2 is present in GL15 cells after 3 days of culturing
in serum starvation conditions, as evaluated by using the
anti-phospho-JAK2 (Tyr1007/1008) antibody (Fig. 1B). The
levels of phospho-JAK2 are not significantly affected by the
serum starvation conditions, as evaluated by densitometric
analysis and normalization against the ß-actin content
(Fig. 1B). The main explanations of this result are: i) In
the absence of serum in the culture medium, autocrine and
paracrine loops are generated by endogenously produced
growth factors and their receptors, able to elicit cellular
responses involving the activity of JAK2, ii) an altered control
of JAK2 activity, deriving from the genetic abnormalities
involving the JAK2 gene or from the presence of abnormally
activated transduction systems.
In order to investigate if, in analogy with some leukaemia
cells, genomic alterations could be the basis for the consti-
tutive activation of JAK2, the localization of the JAK2 gene
was analysed by FISH, using the clone RPI-134N20 probe.
Our results show a normally localized hybridization signal on
both chromosomes 9, absent on del(9)(p22) (Fig. 1C).
Moreover, we analysed the possible occurrence of a
specific mutation of the JAK2 gene, observed in patients
affected by Polycytemia Vera. Screening analysis with
dHPLC was used. A wild-type chromatogram, with one single
peak indicative of no mutation, was obtained in the GL15
cells and in the negative control. The electropherograms from
the GL15 cells were not equal to those generated from the
positive control (Polycythemia Vera) (data not shown).
Therefore, at this state of experimentation, abnormalities of
the JAK2 gene are not directly involved in the constitutive
activation of JAK2 in GL15 cells.
We evaluated the effects of 10 μM tyrphostin AG490 (the
inhibitor of JAK2 activity) on JAK2 autophosphorylation by
using the anti-phospho-JAK2 (Tyr1007/1008) antibody. Our
results show that, 3 days after treatment with AG490, the
active form of JAK2 was significantly reduced (Fig. 2A).
The biological response of GL15 cells to AG490 was
analysed. Our working hypothesis is that the response of at
least subpopulations of GL15 cells could mimic the response
of normal or mutated astrocytic precursors. In this respect it
should be noted that AG490 has been shown to be ineffective
on normal human astrocyte growth (24). Three days after
treatment, tyrphostin AG490 significantly inhibits GL15 cell
growth (Fig. 2B). Moreover, a huge morphological effect is
observed by contrast phase microscopy: A pheno-type
characterised by very thick and elongated processes arises
(Fig. 2C).
In order to verify if these effects could result from an
induction of differentiation, we analysed the expression of
the glial fibrillary acidic protein (GFAP), the marker of mature
astrocytes (25,26), by immunocytochemistry and Western
blotting. The immunocytochemistry analysis shows the same
mosaic pattern of GFAP expression in GL15 cells both in the
control conditions and after treatment with tyrphostin AG490
(Fig. 2D). Immunoblot analysis confirms that the level of
GFAP expression is not affected (Fig. 2E). Therefore
tyrphostin AG490 does not induce differentiation in GL15
cells.
When we investigated by immunocytochemistry whether
an abnormal polymerization of ß-tubulin, the basic component
of the cytoskeleton and of the mitotic spindle, was involved
in the acquired phenotype, the main results were: i) ß-tubulin
constitutes the scaffold for the elongated processes, and ii)
mitotic figures are totally absent in the AG490-treated cells,
while mitotic figures, either in metaphase or in anaphase, are
evident in the control cells (Fig. 3A).
A possible explanation is a cytostatic effect: AG490
inhibits JAK2-mediated signal transduction systems, elicited
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by endogenously produced growth factors and cytokines
able to promote the G0/G1 transition of the cell cycle. This
possibility was investigated by cell cycle analysis, performed
after propidium iodide staining.
Tyrphostin AG490 deeply affects the cell cycle profile: A
significant decrease of the G0/G1 phase combined with a
significant increase of the S phase was observed (Fig. 3B).
This result indicates that the main effect of AG490 is an S
phase arrest which also involves a partial impairment of the
G2/M transition. In fact the S phase arrest should imply a
significant reduction of the percentage of cells in the G2/M
phase unless the G2/M phase was similarly affected. Due to
the fact that, when inspecting the nuclear morphology by
DAPI staining (data not shown) and mitotic spindles by
immunocytochemistry, we did not observe any mitotic figures
in the AG490-treated cells, we concluded that, the G2, and not
the M phase, must be affected.
It should be noted that an S phase arrest is quite unusual
if we consider that the inhibition of transduction systems
downstream the activation of the growth factor and cytokine
receptors has, as a main effect, a G1 phase arrest.
We can not rule out other possibilities: An abnormal and
abortive stimulation of the G1/S transition, or an induction of
apoptosis occurring during the S and the G2 phases of the cell
cycle.
A significant increase in the percentage of cells with a
sub-G0/G1 nuclear DNA content is usually observed when
apoptosis occurs during the G0/G1 phase. A more complicated
pattern of the nuclear DNA content can result from an
induction of apoptosis in the other phases of the cell cycle: In
this case the increase in the percentage of cells with a sub-
G2/M DNA content could be misleadingly evaluated as an
increase in the percentage of cells in the S phase. In order to
check this possibility, the induction of apoptosis by AG490
was investigated by an ELISA method aimed at quantifying
the presence of cytoplasmic nucleosomes. Our results show a
very low induction of apoptosis (Fig. 3C). Therefore tyrphostin
AG490 actually induces an increase in the percentage of cells
in the S phase of the cell cycle.
Our results constitute the first demonstration that, in
analogy with some leukaemia cells, glioblastoma cells can
display a constitutive activation of JAK2. Moreover, the
unusual S phase arrest induced by tyrphostin AG490 can
constitute a specific response of glioblastoma cells in which a
combination of glial precursor characteristics and genetic
alterations occurs.
Discussion
There are many reports concerning the possibility that glioma
cells could originate from mutated glial precursor cells (1,2).
This research constitutes an important topic because some
molecular mechanisms, active during glial cell development
but absent in adult glia, could be involved in the pathogenesis
of gliomas and, therefore, could be targets for a specific
pharmacological approach. It is difficult to reproduce in vitro
the complexity of cell types observed in human glio-
blastomas. However, the use of glioblastoma cell lines allows
experimental approaches able to select specific cell populations
and to study specific molecular mechanisms involved in the
control of cell growth and differentiation.
Our study shows that the GL15 glioblastoma derived
human cell line displays some characteristics of astrocyte
restricted precursors. Moreover, in analogy with some
leukaemia cells, the active form of JAK2 is present in GL15
cells, also in the absence of exogenous growth factors and
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Figure 1. Vimentin and nestin expression, phospho-JAK2 levels and JAK2
gene localization in GL15 cells. (A) Immunoblot analysis of vimentin and
nestin, after 3 days of subculturing in the presence (S) and in the absence (SF)
of serum. (B) Immunoblot and densitometric analysis of phospho-JAK2,
after 3 days of subculturing in the presence (S) and in the absence (SF) of
serum. (C) FISH experiment with the clone RP1-134N20 in green which
hybridizes with both normal chromosomes 9 (arrow). No green signal is
present on del(9)(p22).
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Figure 2. Effects of 10 μM AG490 on GL15 cells 3 days after treatment in serum-free conditions. (A) Immunoblot and densitometric analysis of the
phosphorylated (Tyr1007/1008) form of JAK2. Ctrl, control; AG490, 10 μM tyrphostin AG490. (B) Cell count. Ctrl, control; AG490, 10 μM tyrphostin
AG490. (C) Contrast phase microscopy. (a) Control, (b) 10 μM tyrphostin AG490 (original magnification x400). (D) Immunofluorescence staining of GFAP.
(a) Control, (b) 10 μM tyrphostin AG490 (original magnification x400). (E) Immunoblot analysis of GFAP expression. Ctrl, control; AG490, 10 μM
tyrphostin AG490. *P<0.05, **P<0.001, Student's t-test. 
Figure 3. Effects of tyrphostin 10 μM AG490 on the GL15 cell cycle, 3 days after treatment in serum-free conditions. (A) Immunofluorescence staining of
ß-tubulin. (a) Control, (b) 10 μM tyrphostin AG490 (original magnification x100), (c) control, (d) 10 μM tyrphostin AG490 (original magnification x400).
(B) Cell cycle analysis. Ctrl, control; AG490, 10 μM tyrphostin AG490. (C) ELISA detection of cytoplasmic nucleosomes. Ctrl, control; AG490, 10 μM
tyrphostin AG490.
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cytokines. The expression of JAK2, evident during CNS
development but undetectable in the adult brain, could be
related to the precursor characteristics of GL15 cells. On the
contrary, the constitutive activation of JAK2 does not depend
on the chromosomal translocations affecting the JAK2 gene:
We found a normal localization of the JAK2 gene. Moreover,
the mutation of the JAK2 gene, observed in patients affected
by Polycythemia Vera, is absent in GL15 cells. Therefore
a direct involvement of the JAK2 gene abnormalities in the
constitutive activation of JAK2 is ruled out. The consti-
tutive activation of JAK2 could be a downstream effect of
abnormally activated transduction systems.
The abnormally activated JAK2 could be the basis for the
constitutive activation of the signal transducer and activator
of transcription 3 (STAT3), observed in GL15 cells (27) and
in human glioblastomas (24). This idea is supported by the
fact that: i) The abnormal expression of cytokines, and their
receptors, belonging to the interleukin 6 family and acting
during glial cell development (28-34), has been detected in
human glioblastomas: These cytokines elicit transduction
systems involving the activity of JAK2 and leading to the
activation of STAT3. ii) Chromosomal abnormalities, leading
to the over-expression of the epidermal growth factor (EGF)
receptor, are a common finding in human glioblastomas (1,2)
and are observed in GL15 cells: It has been recently reported
that the over-expression of the EGF receptor can lead to a
JAK2-mediated activation of STAT3 in primary esophageal
keratinocytes (35). We have considered JAK2 as a possible
target for a specific pharmacological approach.
Our results show that, in GL15 cells, the inhibition of
JAK2 activity by tyrphostin AG490 induces, as its main
effect, an S phase arrest in the cell cycle progression. This S
phase arrest induced by AG490 constitutes an unusual cellular
response, because it has been demonstrated that in several
cellular systems AG490 induces a G1 phase arrest (18,36). A
possible target of tyrphostin AG490 is the activation of the
cyclin-dependent-kinase 2 (CDK2) (37), an enzyme involved
in the control of the G1 and S phase progression. In fact 30 μM
AG490 has been reported to inhibit the activation of CDK2
by acting on an unknown mechanism. It is possible that this
or other unknown mechanisms are active in GL15 cells, and
that these mechanisms are elicited by the abnormal activation
of JAK2. The presence, in glioblastoma cells, of abnormal
biochemical pathways, specifically inhibited by AG490, is
confirmed by a report showing that 25-50 μM AG490, able
to inhibit STAT3 activation and unable to affect the cell
growth of normal human astrocytes, induces apoptosis in the
U251 glioblastoma derived human cell line (24).
Our hypothesis is that, in GL15 cells, the activation of
JAK2 becomes part of an altered biochemical background
which constitutes a specific characteristic of subpopulations
of glioblastoma cells. The presence of JAK2-mediated signal
transduction systems (derived from the glial precursor
characteristics of GL15 cells) as well as the altered activity
of biochemical pathways involved in the control of cell cycle
progression (derived from the neoplastic characteristics of
GL15 cells) are the basis of the altered biochemical
background. An abnormally activated biochemical pathway,
absent in normal cells, could be the target of the specific
action of tyrphostin AG490 in glioblastoma cells.
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